Biophagy presents “Autophagy: From Model Systems to Therapeutic Opportunities, 2/19/19, Keystone Symposium, Santa Fe, NM. By jordan|2022-02-01T19:10:18+00:00February 1, 2022|2019-announcements|0 Comments Share This Story, Choose Your Platform! FacebookTwitterRedditLinkedInWhatsAppTelegramTumblrPinterestVkXingEmail About the Author: jordan Related Posts Biophagy is awarded a second NMSBA leverage grant with Sandia National Laboratories to lead a team of three companies (including Avisa Pharma and Omphalos Biosciences) towards identifying a lead autophagy stimulant in tuberculosis. The team will be working with human TB bacteria (M. tuberculosis, attenuated) and human macrophages to determine the effects of autophagy on isoniazid antibiotic enhancement and on U-TAID (proprietary antibiotic). They will also use an siRNA knockdown cell line to delineate the direct role of autophagy in compound activity and antibiotic enhancement. Biophagy is awarded a second NMSBA leverage grant with Sandia National Laboratories to lead a team of three companies (including Avisa Pharma and Omphalos Biosciences) towards identifying a lead autophagy stimulant in tuberculosis. The team will be working with human TB bacteria (M. tuberculosis, attenuated) and human macrophages to determine the effects of autophagy on isoniazid antibiotic enhancement and on U-TAID (proprietary antibiotic). They will also use an siRNA knockdown cell line to delineate the direct role of autophagy in compound activity and antibiotic enhancement. Leave A Comment Cancel replyComment Save my name, email, and website in this browser for the next time I comment.
Leave A Comment